This prestigious honour celebrates his transformative leadership, innovative contributions to healthcare advancement, and unwavering commitment to elevating medical systems in alignment with Saudi Arabia’s ambitious socio-economic diversification agenda, Vision 2030.

With over 26 years of distinguished experience, Maj. Gen. (Dr.) Al Faraidy has emerged as a pioneering force in healthcare transformation. His unique combination of clinical excellence in interventional cardiology and strategic executive leadership has enabled him to guide major healthcare institutions through meaningful change and sustainable progress.

As CEO of King Fahd Military Medical Complex and a board member of key national institutions, including the Health Holding Company, he plays a vital role in shaping the future of healthcare in Saudi Arabia and influencing broader regional advancements.

Global Recognition And Academic Excellence
Maj. Gen. (Dr.) Al Faraidy’s influence extends far beyond national boundaries. In 2025, he was honoured as one of the “Top 100 Global Power Leaders” and the “Global 200 Inspirational Leaders” by global marketing giant White Page International. He also received the Stevie Award for “Thought Leader of the Year” and the Tribute Award for “Outstanding Contribution in Serving the Nation in Medicine.”

The veteran doctor’s academic credentials reflect a lifelong pursuit of excellence. He holds a Master of Science in Health Administration from the University of Alabama at Birmingham and has completed prestigious executive programmes at Harvard Business School, MIT Sloan School of Management, and London Business School. His keen knowledge and interest in artificial intelligence (AI) applications in healthcare, crisis management, and digital transformation have positioned him at the forefront of global health innovation.

A Vision Aligned With National Transformation
Maj. Gen. (Dr.) Khalid Al Faraidy’s leadership philosophy is deeply rooted in the principles of Saudi Vision 2030, which positions healthcare as a cornerstone of national development. As Chairman of the Nomination and Remuneration Committee and Board Member of the Founding Board Council and Executive Committee in the Eastern Cluster at the Health Holding Company, he has been instrumental in shaping the Kingdom’s healthcare strategy and governance frameworks.

His initiatives aim to advance value-based care models, speed up digital health transformation, and reinforce regulatory standards to ensure that healthcare delivery is effective and centred on patients.

Beyond his role at HHC, Maj. Gen. (Dr.) Al Faraidy has held influential positions within the Eastern Health Clusters, leading critical committees responsible for audit, risk management, compensation, and regional development. These appointments highlight the confidence placed in his strategic vision and his proven ability to navigate complex healthcare systems toward enhanced performance and improved health outcomes.

Career Defined By Service And Impact
Maj. Gen. (Dr.) Khalid Al Faraidy’s career uniquely combines clinical expertise with executive skills. He has served as President of the Saudi Arabian Cardiac Interventional Society. His leadership of the Strategic Cardiac Hajj Interventional Programme (SCHIP) demonstrated his ability to manage high-stakes, mission-critical operations with precision and compassion. This reflects his enduring commitment to community service, professional development, and ethical leadership.

Transforming institutions through innovation
A perfect example of Maj. Gen. (Dr.) Khalid Al Faraidy’s capacity to drive institutional excellence is his leadership at King Fahd Military Medical Complex (KFMMC). The facility achieved a historic milestone by becoming the first military hospital outside the United States to receive MAGNET Recognition for Nursing Excellence, a testament to its commitment to clinical quality and workforce empowerment.

He pioneered the establishment of the C.A.R.E. Office (Clinical Allocation and Resource Excellence), revolutionising clinical operations, staff deployment, and resource optimisation. Through the innovative TELL ME Project, he fostered transparent communication channels between employees and leadership, cultivating a culture of trust, engagement, and continuous improvement.

During his leadership, KFMMC successfully earned its fourth Joint Commission International (JCI) re-accreditation, reinforcing adherence to global standards in patient safety and care quality. Comprehensive facility renovations were also completed, significantly enhancing both patient experience and staff satisfaction while modernising the healthcare environment.

Empowering Change Through Medical Excellence
International Finance recognises Maj. Gen. (Dr.) Khalid Al Faraidy is not merely a leader of today, but also a visionary architect of tomorrow’s healthcare landscape, where innovation is guided by compassion and excellence becomes the standard. His career embodies more than a collection of achievements; it represents a narrative of purpose, resilience, and tireless dedication to improving health outcomes for all.

At a time when healthcare systems worldwide face unprecedented challenges, Maj. Gen. (Dr.) Khalid Al Faraidy stands for transformative leadership. His approach, grounded in integrity, strategic foresight, and measurable impact, offers a compelling blueprint for the future. The honour at the IFM Awards testifies to his management style, showing what is possible when medical expertise and visionary leadership unite in service to society.

The post Maj. Gen. (Dr.) Khalid Al Faraidy: Spearheading transformative healthcare in Saudi Arabia appeared first on International Finance.

Established in 2010, QNH has become a leader in medical innovation and excellence, setting new standards for patient safety in the region, and providing specialised care across 34 medical specialities and subspecialties, with a capacity of 135 in-patient bed units.

Over time, QNH has sought to continuously enhance its medical services by ensuring it operates to the highest standards of quality and patient care. The hospital has secured national and international accreditations like CBAHI, JCI, CAP, AABB, and ACHC.

Its facilities include an ambulatory setting with outpatient departments (OPD Clinics), a comprehensive emergency department, specialised units for dialysis, intensive care for adults, pediatrics, and neonates. The hospital also supports general medical and surgical wards for both male and female patients, labour and delivery rooms, operating theatres, a cardiac catheterisation lab, and well-equipped in-patient and out-patient pharmacies.

Qassim National Hospital places patient safety at the heart of its mission, implementing rigorous safety protocols and advanced technology to ensure the safest and most effective care possible. The hospital integrates electronic medical records (EMR) systems to reduce errors, employs real-time patient monitoring, and uses sophisticated diagnostic tools for early detection and timely intervention. QNH’s safety framework extends beyond traditional care settings with specialised programmes in infection control, medication safety, and patient education initiatives. These measures have been instrumental in achieving a low incidence of preventable errors and hospital-acquired infections.

Accreditations

“For healthcare facilities, accreditation seeks to promote organisational change through an approach that values the level of progress achieved within a validated reference framework. The aim is to analyse the role played by accreditation through the experience perceived by health professionals during the process of self-assessment and external evaluation, taking into account three dimensions of analysis: focus on the patient, internal organisation and leadership, and impact on the clinical aspects of healthcare,” QNH told International Finance.

“Accreditation serves as the bedrock of trust and quality assurance across industries. Whether it’s the health care service we receive, the food we eat, the buildings we work in, or the technology we rely on, accredited bodies ensure that standards are not just met but consistently upheld. This invisible framework guarantees that products and services are safe, reliable, and of high quality,” it added.

QNH began its accreditation journey in 2017 by obtaining the Gold Seal from the Joint Commission. In 2018, it achieved national mandatory accreditation from CBAHI. The successful run continued with the addition of laboratory and blood bank accreditations, which were awarded by the College of American Pathologists (CAP) and the Association for the Advancement of Blood and Biotherapies (AABB) in 2022 and 2023, respectively. This progression underscores QNH’s commitment to providing the safest care possible.

Reaccreditation surveys for JCI and CBAHI took place in 2023 and 2024, yielding outstanding results. Earlier this year, the hospital received the ACHC accreditation. The reaccreditation surveys for AABB and CAP were also conducted, producing exceptional results. The robust accreditation journey guaranteed that patients receive care in an environment that meets thousands of international and national standards for safer healthcare delivery, while also ensuring that staff work in a physically and psychologically safe environment.

The post Qassim National Hospital: A leader in patient safety & excellence appeared first on International Finance.

With a solid history of success and a strong emphasis on digitisation, aligned with Saudi Arabia’s “Vision 2030” economic diversification agenda, Nahdi is actively shaping the future of healthcare while supporting regional growth and development.

Extensive Network And Market Reach

With the purpose of adding beats to the lives of its guests every day Nahdi currently operates over 1,100 pharmacies across 140+ cities and villages in Saudi Arabia and the UAE, along with 10 state-of-the-art multispecialty clinics operational in the Kingdom.

“This extensive network allows Nahdi to serve millions of guests daily, reaching 97% of the Saudi population. This impressive reach reinforces Nahdi’s position as a trusted partner in health and wellness, making it a vital contributor that serves the growing ambitions of these rapidly changing markets,” the company told International Finance.

Commitment To Innovation And Sustainability

Nahdi’s mission is to exceed its guests’ expectations by providing superior personalised life care experiences every day everywhere, thereby emerging as the “most loved and trusted health wellbeing partner” of its guests.

Keeping the goal in mind, the venture is putting itself at the forefront of innovation, demonstrated by establishing the first bonded zone for a private company in Saudi Arabia. The company boasts a solid IT infrastructure with sophisticated last-mile logistics that serve 97% of the population within two hours. This capability, combined with a global platform serving customers directly from outside Saudi Arabia, positions Nahdi as a leader in integrated healthcare services.

Focus On Employee Development

With a total staff count exceeding 10,000 across the company and its subsidiaries, Nahdi prioritises employee training and development. The company also has strong partnerships with universities, providing over 2,000 training opportunities annually and conducting more than 500,000 hours of training. This commitment to nurturing local talent strengthens the workforce and enhances service delivery, contributing to Nahdi’s reputation as a top employer in the region.

Strong Brand Equity And Customer Loyalty

Nahdi’s brand equity is reinforced by a solid loyalty programme, with over 80% of revenue generated from its Nuhdeek Guests. The company boasts a brand equity score of 6.9, double that of its nearest competitor in the market. This loyalty not only drives revenue but also fosters long-term relationships with customers, ensuring sustained growth and profitability.

“Investing in Nahdi Medical Company means being part of a transformative journey in the healthcare sector. With its extensive network, commitment to innovation, focus on employee development, and strong brand loyalty, Nahdi is well-positioned for continued success. As it constantly adapts to evolving needs, aligning with the goals of Vision 2030 and contributing to regional growth, Nahdi offers boundless potential and sustainable returns for investors,” the company concluded.

The post Nahdi: A leader in pharmacy retail & integrated primary healthcare appeared first on International Finance.

The company, which has a branch in Riyadh, completed its hospital project in Buraydah City, on an area of 90,000 square meters.

The facility, known as Al-Qassim National Hospital, provides top-notch medical care with state-of-the-art patient care and safety, through evidence-based medicine, a solid learning environment and a group of dedicated employees, empowered with the vision of becoming the most aspiring healthcare organization, rendering exceptional care and heart-felt experience in the region and across the Kingdom.

A recent milestone for this healthcare facility was the certificate of accreditation of health services quality, JCI “Joint Commission International”.

“Al-Qassim National Hospital obtained a certificate of accreditation of health services quality, JCI ‘Joint Commission International’, after passing the international joint body test, which is composed of a working team that came from the United States of America and stayed in the hospital for 4 days,” the hospital told the International Finance.

The CEO of Al-Qassim Medical Services Company, Prof. Sultan Fahd Al Nohair now indicates that this accreditation has emerged as evidence of the hospital’s commitment to providing the best levels of health care to its patients and its ability to provide a safe environment for the patients, visitors, and employees.

The accreditation certificate came against the backdrop of the evaluation process that included examining the hospital’s systems and policies, apart from the understanding of the working principles of its healthcare staff and medical technicians, along with the procedures of patients’ entry and exit, the quality of care provided to patients.

Also, factors considered for the accreditation certificate were the standards of diagnostic radiology and laboratory services, the systems of using a system of safe medication use, the correct use of information systems while protecting the privacy of patient information, hospital documentation for contracts and the credibility of scientific certificates of doctors and employees, and an overall preview of the building and its compatibility for safety rules.

“JCI Re-accreditation was successfully obtained under the leadership of Prof. Sultan Al Nohair – CEO of Al-Qassim Medical Services Company with his guidance, continuous support, and encouragement to everyone, and with the utmost effort of all the hospital staff, we once again achieved one of our hospital goals,” the hospital commented further.

Al-Qassim Medical Services Company also obtained the accreditation of the “Saudi Central Board for Accreditation of Healthcare Institutions” (CBAHI) after passing a comprehensive and integrated assessments to determine its commitment to the quality and safety standards set by the Board.

“These standards are among the most advanced and accurate national standards for health facilities to provide the best and safest medical services for reviewers,” the hospital commented further.

Professor Sultan Fahd Al Nohair, CEO of the Al-Qassim Medical Services Company, told International Finance that the healthcare facility was proud of having obtained the accreditation of the “Saudi Central Board for Accreditation of Healthcare Institutions” (CBAHI).

He also noted that this accreditation represented a strong motivation to move forward in applying more quality standards and continuous improvement on the medical, technical or administrative levels.

The hospital reiterated its pledge to strive to implement its vision of being a healthcare facility of outstanding and high moral values among the best treatment centres in the Kingdom.

Honours Galore

Along with CBAHI and JCI certifications, Al-Qassim National Hospital also obtained the accreditation of the “College of American Pathologists” (CAP) after passing a comprehensive and integrated assessment to determine its commitment to the quality and safety standards set by the Board.

Talking about the achievement, Professor Sultan Fahd Al-Nohair, noted that this feat “represents a strong motivation to move forward in applying more quality standards and continuous improvement whether on the medical, technical or administrative level”.

Al-Qassim National Hospital also obtained the accreditation of the “Association for the Advancement of Blood & Biotherapies” (AABB) after passing a comprehensive and integrated assessment procedure.

“I am pleased and my colleagues, the members of the boards of Directors of Al Qassim Medical Services Company, are committed to welcoming you. Praise be to God. Efforts are continuing to improve and develop Al Qassim National Hospital to provide distinguished health services with high quality, by attracting the best specialized medical personnel, and training the workforce in various fields,” said Faisal bin Mohammed Shaker, the Chairman of Board of Directors, while interacting with the International Finance.

“The company’s management is committed to working hard with all community institutions in supporting health education activities and caring for healthy days, which enhances community awareness of healthy behaviours. Al Qassim Medical Services Company has also paid sufficient attention to employing, qualifying, and training Saudis, and contributing with civil Society institutions in all that develops our society,” the official added further.

“I thank all the shareholder of the company for their support and assistance to the company, and we hope that we will achieve all that they aspire to in terms of progress and prosperity in the company’s business, a rewarding return on investment and the provision of distinguished health services to the Qassim community and neighbouring regions,” he concluded.

The post Al-Qassim National Hospital leads the way in revolutionary medical solutions appeared first on International Finance.

The company, with its core focus on ‘Wealth and Health’, has played a crucial role in ensuring the long-term success of both the organization and its stakeholders.

As of 2023, Bangkok Life Assurance Public Limited has established itself as Thailand’s leading health insurance provider, offering outstanding insurance products and providing customers with a sense of security and well-being.

Now, let’s explore the key factors that have played a significant role in the company’s market dominance.

Acing The Wealth Care Game

A strong and competitive wealth management product is one that effectively caters to the evolving needs of customers while maintaining simplicity.

Bangkok Life Assurance has successfully cracked this winning formula in the market. Its life insurance products are tailored to individual needs and are accompanied by clear and easily comprehensible terms and conditions, making them accessible to everyone.

“The company takes extra care when it comes to designing participating products and unit-linked products which both come with investment features. With its team of expert investment analysts and financial advisors, Bangkok Life Assurance can meet the needs of the customers when it comes to comprehensive financial planning,” Bangkok Life Assurance told International Finance.

A Wide Portfolio Of Health Coverage Plans

Bangkok Life Assurance offers an extensive selection of health coverage plans, including ‘Prestige Health,’ ‘BLA Happy Health,’ and ‘Value Health.’ Each plan is designed to address specific customer needs.

In addition to its highly sought-after range of health insurance products, the company is committed to providing exceptional health services with a customer-centric approach. This ensures that customers receive top-quality and dependable services, fostering a positive sentiment towards their insurance commitments with Bangkok Life.

“Bangkok Life Assurance never stops developing health services in addition to great insurance products to deliver the best experience to its customers,” said the company, while talking about the ‘BLA EveryCare’, which is a complete health service program designed to capture the customers’ needs at every point of their health journey.

Let’s take a closer look at the ‘BLA Medevac Hotline’ as a compelling case study. This product is a valuable resource during medical emergencies and is the result of a collaborative effort between Bangkok Life Assurance and its esteemed hospital partners. The initiative ensures the secure transfer of patients to and from Thai hospitals throughout their treatment, emphasizing the crucial principle of “Speed Means Everything” in healthcare crises.

Additionally, let’s discuss ‘TeleMed Plus,’ an online doctor consultation service that helps alleviate customers’ concerns about the early symptoms of a health crisis. It assists them in making informed decisions about whether hospital admission is necessary, providing peace of mind and timely guidance.

“The service can be enjoyed at the customer’s fingertip through a phone or video call. An additional and free service of the same nature is BLA Health Partner offered by the company’s very own medical centre to every one of its customers,” stated Bangkok Life Assurance.

“For customers who need extra care after a hospital stay, Bangkok Life Assurance also offers services such as a driving home service, a practical nursing service and a physiotherapy service to ensure a smooth transition from the hospital to the patient’s home. The company also provides an Elderly Center and Home Health Care Information Service for those who require rehabilitation after hospital discharge,” it noted.

In times of crisis, Bangkok Life Assurance goes beyond its role as a health coverage provider and becomes a trusted friend for patients, guiding them through every stage of their treatment. BLA acts as a reliable financial institution that not only offers health coverage but also provides support and assistance when it is needed the most.

Promoting Quality Services Through Strong Partnerships

Bangkok Life Assurance is taking its health services to new heights by collaborating closely with its network hospitals. The company aims to ensure a seamless and positive customer journey, while also streamlining the claim reimbursement process for families of patients, making it hassle-free, fast, and efficient.

In line with this commitment, the company has introduced recognition awards, such as the ‘BLA Smart Hospital Awards,’ to acknowledge outstanding healthcare services provided by its network hospitals. These awards cover categories like best health check-up services, best customer services, and best agent services.

Additionally, the ‘BLA Best Caring Awards’ honour the insurance agents and staff who are the driving force behind Bangkok Life Assurance’s success. Their dedication and excellent service are recognized through these awards, highlighting the company’s focus on delivering caring and attentive experiences to its customers.

These awards reflect the company’s dedication to quality services, not only within its own operations but also within its collaborative partner ecosystem. Bangkok Life Assurance strives to make the concept of “caring” tangible in every action it takes.

Rather than resting on its laurels, Bangkok Life Assurance Public Limited remains committed to its ongoing efforts.

“Stepping into a sustainable future not only of itself, but also of Thailand, Bangkok Life Assurance will continue to offer the best insurance products and services to contribute to the sustainable health and wealth of Thai citizens,” BLA concluded.

The post Bangkok Life Assurance: Redefining health insurance excellence appeared first on International Finance.

Metropolitan Group Holdings, the holding company that owns the two hospitals, is sold by Evercare Health Fund for USD 54.9 million to minority co-owner Metro Group Plc, which currently holds a 41.8% stake in the business.

The combined annual revenue of the two hospitals was over Sh1 billion, according to the Competition Authority of Kenya (CAK) data.

The 134 beds at Metropolitan Hospital and the 42 at Ladnan provide the two facilities with 5.8% of the 3,000 private hospital beds in Nairobi County.

The Gates Foundation, TPG Rise Fund, IFC, British development fund BII (formerly CDC), US development fund DFC, Philips, and Medtronic are among the investors in the Texas Pacific Group (TPG), which manages the fund.

It runs healthcare institutions in developing nations throughout South Asia and Africa.

Once the deal is done, the organization that founded Metropolitan Hospital 27 years ago will again hold the majority of the hospital’s stock.

In 1995, Metro Group, then doing business as Metropolitan Health Services (MHS), opened a hospital in Nairobi’s Buru Buru Estate. Later, the company sold some of its shares to the general public, bringing the total number of shareholders to over 500.

Abraaj Holdings was initially invited in by the group, led by Dr Kanyenje Gakombe and Dr Robin Michira, as an outside investor in the hospital.

After that, Metro mainly focused on financial assets and commercial real estate, with an asset base worth more than Sh560 million.

Bill Gates-backed Evercare became a shareholder in Metropolitan Group Holdings in 2019 following the collapse of Abraaj, once the largest buyout fund in the Middle East and North Africa, due to a dispute with investors over the use of funds in its healthcare fund. The Dubai-based company then filed for provisional liquidation in 2018.

The post Bill Gates-backed Evercare sells its stake Kenya hospitals appeared first on International Finance.

This marks the largest product liability class action settlement in Australian history and is pending approval from the federal court.

The net-like meshes, which can take the shape of a “sling,” “tape,” “ribbon,” “mesh,” or “hammock,” are intended to treat pelvic organ prolapse by providing weak pelvic organs with long-term support and to repair damaged tissue.

Johnson & Johnson was accused of failing to adequately evaluate the devices and downplaying their risk to both surgeons and patients in the class actions brought in Australia by Shine Lawyers.

Mesh exposure and erosion, which occur when the mesh pierces the vaginal wall or slashes through internal tissue, vaginal scarring, fistula formation, painful sex, and pelvic, back, and leg problems are among the issues that women experienced. Some of these issues can develop years after surgery and can be challenging to resolve.

The first class action was filed in federal court on October 15, 2012, and it took seven months, from July 2017 to February 2018, to reach a verdict.

A historic ruling in favour of the 1,350 women who participated in the class action who had mesh and tape products implanted to address pelvic prolapse or stress urinary incontinence was handed down in November 2019.

In March 2021, the full court of the federal court dismissed an appeal from Johnson & Johnson Medical and Ethicon.

The principal judge’s finding that the mesh device’s marketing was likely to mislead or deceive was accepted by the full court.

The court dismissed Johnson & Johnson’s legal team’s arguments that manufacturers are exempt from liability with regard to hazards or problems that should be known to doctors or that surgeons and doctors can find out about on their own and warn of.

The court determined that even if not all medical products can be risk-free, patients could expect those products to carry adequate warnings about potential hazards, even if those dangers are unlikely to occur.

The high court rejected Johnson & Johnson Medical’s request for extraordinary leave to appeal in November 2021.

Women who received their implants on or after July 4, 2017, and who were unable to join the first class action, filed the second class action in April 2021.

According to Rebecca Jancauskas of Shine Lawyers, the payment will aid in meeting the women’s ongoing medical needs.

The post Pelvic mesh class action: Johnson & Johnson reaches record settlement appeared first on International Finance.

The four-day event saw 3,500 exhibitors from over 60 countries that showcased its innovation and technology. It also offers a platform for cutting-edge technology and the latest innovations designed to tackle the most pressing health challenges of today and tomorrow.

The Medlab Middle East Exhibition is regarded as the region’s leading exhibition for the laboratory industry, is held in parallel to Arab Health. During the event, a series of panel discussions and keynote presentations from leaders within the industry will be held that will highlight the latest advancements within the sector. Medlab Middle East will showcase the latest innovations from the laboratory industry via a range of product displays and talks.

Commenting on the opening, Solenne Singer, Group Director for Informa Markets, told the media, “The next four days are an opportunity to celebrate the healthcare and laboratory industries while also providing a stage to showcase thousands of products to a global audience all under one roof. A vital attribute of both exhibitions is the platform for peer-to-peer networking while fostering knowledge through insights and expert analysis as part of the CME conferences.”

The post Sheikh Hamdan opens Arab Health and Medlab in the Middle East appeared first on International Finance.

Murshed Al Redaini, group chief executive officer of Yas Holding, told the media, “IDS provides a robust platform that complements our strengths in the pharmaceutical sector. This investment also underscores our commitment to the UAE Vision 2030 and is in line with our focus to establish a well-entrenched healthcare business. We are confident IDS’ business operations will synergise appreciably with our other healthcare companies.”

IDS was established in 1968 and it partners with leading multinational corporations in the UAE to supply a diverse product portfolio across a range of therapeutic classes like antibacterial, asthma, hypertension, diabetes, muscle relaxant, cardiovascular, anticoagulant, anti-rheumatic, and others.

The company also has a proven track record of creating significant long-term value by successfully integrating acquisitions into its growing portfolio of assets. This latest acquisition aligns with the company’s overall strategy and brings attractive opportunities offering substantial synergies.

Since its inception, the company has expanded significantly and has also acquired Gulf Inject, Geltec Healthcare and WellPharma Medical Solutions (WMS) in 2021. GHH’s portfolio includes biopharma, manufacturing, medical supply chain, hospital and clinic management, healthcare technology, and occupational health and wellness. Yas Holding has 7,500 employees and more than 60 operating subsidiaries and has expanding business interests in agriculture, food, healthcare, education, aviation, real estate, FMCG, technology & services.

The post YasHoldings acquire Al Ittihad drugstore to boost its healthcare portfolio appeared first on International Finance.

According to the ESG, investments have increased more than five times when compared to the $464 million raised in 2020. In 2016, the funds raised stood at $86 million. The increase in investments in biomedical firms in Singapore is mainly due to the increase in demand since the pandemic.

Ms. Audrey Lok, health and biomedical director at ESG told the media, “This success can be attributed to our maturing ecosystem as well as our ability to attract experienced accelerators and venture capital firms to Singapore, and connect local companies to innovation nodes around the world.”

She further revealed that the innovation ecosystem has grown nearly six times over the last decade. To date, Singapore has recorded around 360 biomedical firms and small and medium-sized enterprises.

Earlier this year, Singaporean biotechnology startup Mirxes Pte secured around $77 million in its Series C funding round. The round was led by CR-CP Life Science Fund to deliver early detection tests for cancer and other diseases.

Other investors that participated in the funding round for Mirxes include Rock Springs Capital, EDBI, CCB International Holdings Ltd. and Keytone Ventures.

It was also reported that Mirxes is in early talks to go public via a blank-cheque company. The biotech startup is planning to list its shares in the US and is in talks with Summit Healthcare Acquisition.

The post Singapore’s biomedical firms raises $600 mn in the first 9 months of 2021 appeared first on International Finance.